Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05265546 · ClinicalTrials.gov registry record · Phase 1

Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain

A Phase 1 study of Perception Disorders, sponsored by University of California, Berkeley.

Recruiting
Registry status
Phase 1
Development phase
80
Enrollment target
1
Study location

NCT05265546 is a Phase 1 study of Perception Disorders that is actively recruiting participants, run by University of California, Berkeley. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05265546, a Phase 1 study of Perception Disorders, is actively recruiting participants, sponsored by University of California, Berkeley.

RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The long-term objective of this project is to characterize how psilocybin affects visual perception and the brain's representation of the visual environment. It is known that psilocybin alters aspects of visual perception, but the underlying brain mechanisms contributing to these effects are poorly understood. The proposed work will address these questions in a large, diverse sample of healthy human subjects by using functional magnetic resonance imaging (fMRI) to measure the brain's responses to visual stimuli. The proposed research will document which brain areas mediate the effects of psilocybin. The technique of fMRI will be employed to measure brain activity in different brain areas while subjects are performing a visual perceptual task.

Conditions Studied

Interventions

  • DRUG Psilocybin

Study Locations (1)

California

  • University of California, Berkeley - Berkeley

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-03-08
Est. Completion 2025-12-31
Phase Phase 1

Sponsor

University of California, Berkeley

72 total trials

What the Registry Record Tells You About NCT05265546

The ClinicalTrials.gov registry entry for NCT05265546 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Berkeley, which has 72 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Perception Disorders appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.

NCT05265546 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05265546 about?

NCT05265546 is a clinical study titled "Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain". The long-term objective of this project is to characterize how psilocybin affects visual perception and the brain's representation of the visual environment. It is known that psilocybin alters aspects of visual perception, but the underlying brain mechanisms contributing to these effects are poorly ...

What is the current status of trial NCT05265546?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-03-08. Estimated completion is 2025-12-31.

What conditions does trial NCT05265546 study?

This clinical trial studies the following conditions: Perception Disorders.

What interventions are being tested in trial NCT05265546?

The interventions under investigation include: Psilocybin (DRUG).

Who is sponsoring clinical trial NCT05265546?

This trial is sponsored by University of California, Berkeley, which has 72 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05265546 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.